DK2847231T3 - Multispecifikke monoklonale antistoffer - Google Patents

Multispecifikke monoklonale antistoffer Download PDF

Info

Publication number
DK2847231T3
DK2847231T3 DK13788439.1T DK13788439T DK2847231T3 DK 2847231 T3 DK2847231 T3 DK 2847231T3 DK 13788439 T DK13788439 T DK 13788439T DK 2847231 T3 DK2847231 T3 DK 2847231T3
Authority
DK
Denmark
Prior art keywords
monoclonal antibodies
specific monoclonal
specific
antibodies
monoclonal
Prior art date
Application number
DK13788439.1T
Other languages
Danish (da)
English (en)
Inventor
Hwai Wen Chang
Jay M Short
Gerhard Frey
Original Assignee
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Llc filed Critical Bioatla Llc
Application granted granted Critical
Publication of DK2847231T3 publication Critical patent/DK2847231T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK13788439.1T 2012-05-10 2013-05-10 Multispecifikke monoklonale antistoffer DK2847231T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261645302P 2012-05-10 2012-05-10
PCT/US2013/040575 WO2013170168A1 (en) 2012-05-10 2013-05-10 Multi-specific monoclonal antibodies

Publications (1)

Publication Number Publication Date
DK2847231T3 true DK2847231T3 (da) 2019-10-14

Family

ID=49551307

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13788439.1T DK2847231T3 (da) 2012-05-10 2013-05-10 Multispecifikke monoklonale antistoffer

Country Status (13)

Country Link
US (3) US9969813B2 (OSRAM)
EP (2) EP2847231B1 (OSRAM)
JP (3) JP6267689B2 (OSRAM)
KR (3) KR101951641B1 (OSRAM)
CN (2) CN108690132B (OSRAM)
AU (3) AU2013259276B2 (OSRAM)
CA (3) CA2872908C (OSRAM)
DK (1) DK2847231T3 (OSRAM)
ES (1) ES2749200T3 (OSRAM)
HK (1) HK1210620A1 (OSRAM)
IN (1) IN2014DN09417A (OSRAM)
MX (2) MX2019001355A (OSRAM)
WO (1) WO2013170168A1 (OSRAM)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2847231B1 (en) 2012-05-10 2019-07-10 Bioatla LLC Multi-specific monoclonal antibodies
KR102423377B1 (ko) 2013-08-05 2022-07-25 트위스트 바이오사이언스 코포레이션 드 노보 합성된 유전자 라이브러리
CA2947605A1 (en) 2014-05-13 2015-11-19 Bioatla, Llc Conditionally active biological proteins
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
US20170260261A1 (en) 2014-08-28 2017-09-14 Bioatla, Llc Conditionally Active Chimeric Antigen Receptors for Modified T-Cells
CA2975852A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
EP3350314A4 (en) * 2015-09-18 2019-02-06 Twist Bioscience Corporation OLIGONUCLEIC ACID VARIANT LIBRARIES VARIANT AND SYNTHESIS THEREOF
KR102794025B1 (ko) 2015-09-22 2025-04-09 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
EP3403098B1 (en) 2016-01-12 2021-09-22 BioAtla, Inc. Diagnostics using conditionally active antibodies
US10697972B2 (en) 2016-01-12 2020-06-30 Bioatla, Llc Diagnostics using conditionally active antibodies
AU2017238172B2 (en) 2016-03-21 2024-06-27 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
PL3455261T3 (pl) 2016-05-13 2022-12-12 Bioatla, Inc. Przeciwciała anty-ror2, fragmenty przeciwciał, ich immunokoniugaty oraz ich zastosowania
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
US11550939B2 (en) 2017-02-22 2023-01-10 Twist Bioscience Corporation Nucleic acid based data storage using enzymatic bioencryption
US20210246227A1 (en) 2017-05-31 2021-08-12 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
US10696965B2 (en) 2017-06-12 2020-06-30 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
KR102794369B1 (ko) 2017-08-01 2025-04-15 에이비 테라퓨틱스 인코퍼레이티드 이중특이 항체 및 그의 용도
CA3075505A1 (en) 2017-09-11 2019-03-14 Twist Bioscience Corporation Gpcr binding proteins and synthesis thereof
CN111565834B (zh) 2017-10-20 2022-08-26 特韦斯特生物科学公司 用于多核苷酸合成的加热的纳米孔
EP4495142A3 (en) 2017-12-22 2025-05-07 Argenx BVBA Bispecific antigen binding construct
US10936953B2 (en) 2018-01-04 2021-03-02 Twist Bioscience Corporation DNA-based digital information storage with sidewall electrodes
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3765516A2 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
SG11202011467RA (en) 2018-05-18 2020-12-30 Twist Bioscience Corp Polynucleotides, reagents, and methods for nucleic acid hybridization
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
SG11202012405WA (en) * 2018-06-14 2021-01-28 Bioatla Inc Multi-specific antibody constructs
US11845797B2 (en) 2018-07-03 2023-12-19 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
SG11202100961UA (en) * 2018-08-21 2021-03-30 Bioatla Inc CONDITIONALLY ACTIVE PROTEINS WITH pH SELECTIVITY
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
AU2019416187B2 (en) 2018-12-26 2025-08-28 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
CN114127112A (zh) 2019-02-21 2022-03-01 马伦戈治疗公司 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
JP2022521751A (ja) 2019-02-21 2022-04-12 マレンゴ・セラピューティクス,インコーポレーテッド 抗tcr抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
GB2599229B (en) 2019-02-21 2024-04-24 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
WO2020176678A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for glp1 receptor
US11492728B2 (en) 2019-02-26 2022-11-08 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
US20230026259A1 (en) 2019-03-08 2023-01-26 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
JP2022550497A (ja) 2019-06-21 2022-12-02 ツイスト バイオサイエンス コーポレーション バーコードに基づいた核酸配列アセンブリ
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
WO2021061829A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for crth2
EP4034564A4 (en) 2019-09-23 2023-12-13 Twist Bioscience Corporation VARIANT NUCLEIC ACID LIBRARIES FOR SINGLE-DOMAIN ANTIBODIES
WO2021084104A1 (en) 2019-10-30 2021-05-06 Bioinvent International Ab Tetravalent antibody molecules
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CN115843312A (zh) 2020-04-24 2023-03-24 马伦戈治疗公司 结合至t细胞相关癌细胞的多功能性分子及其用途
CN116249718A (zh) 2020-08-26 2023-06-09 马伦戈治疗公司 结合至钙网蛋白的多功能性分子及其用途
JP2023540248A (ja) 2020-08-26 2023-09-22 マレンゴ・セラピューティクス,インコーポレーテッド Trbc1またはtrbc2を検出する方法
WO2022046922A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
CA3197047A1 (en) * 2020-10-07 2022-04-14 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
US20250099579A1 (en) 2021-04-08 2025-03-27 Marengo Therapeutics, Inc. Multispecific molecules binding to tcr and uses thereof
WO2023023055A1 (en) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions and methods for optimizing tropism of delivery systems for rna
CN118317944A (zh) 2021-09-14 2024-07-09 雷纳嘉德医疗管理公司 非环状脂质及其使用方法
JP2024533865A (ja) 2021-09-14 2024-09-12 レナゲード セラピューティクス マネージメント インコーポレイテッド 環状脂質及びその使用方法
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
AU2023251104A1 (en) 2022-04-07 2024-10-17 Renagade Therapeutics Management Inc. Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
KR100332139B1 (ko) 1992-11-24 2002-11-30 지.디. 썰 엘엘씨 인터류킨-3(il-3)복합돌연변이폴리펩티드
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
ATE173740T1 (de) 1993-09-22 1998-12-15 Medical Res Council Antikoerper mit geaenderter zielrichtung
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
DE69737867T2 (de) 1996-05-03 2007-10-18 Immunomedics, Inc. Zielgerichtete kombinations-immuntherapie für krebs
US7011812B1 (en) 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
ATE398464T1 (de) * 1998-03-27 2008-07-15 Genentech Inc Synergie zwischen apo-2 ligand und antikörper gegen her-2
US7833528B2 (en) 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
DE60129741T2 (de) 2000-06-20 2008-04-30 Immunomedics, Inc. Zielgerichtete kombinationsimmuntherapie für krebs und infektionskrankheiten
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
KR20030055274A (ko) 2000-10-20 2003-07-02 츄가이 세이야꾸 가부시키가이샤 저분자화 트롬보포에틴 아고니스트 항체
AU2002250081A1 (en) 2001-02-14 2002-08-28 Uab Research Foundation Combined transductional and transcriptional targeting system for improved gene delivery
BR0207267A (pt) 2001-02-19 2004-02-10 Merck Patent Gmbh Proteìnas artificiais com imunogenicidade reduzida
US20050142539A1 (en) * 2002-01-14 2005-06-30 William Herman Targeted ligands
JP4518941B2 (ja) 2002-04-26 2010-08-04 中外製薬株式会社 アゴニスト抗体のスクリーニング方法
ES2368733T3 (es) * 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
AU2013200009B2 (en) * 2002-07-18 2015-05-07 Merus N.V. Recombinant production of mixtures of antibodies
ATE431423T1 (de) 2003-01-21 2009-05-15 Chugai Pharmaceutical Co Ltd Verfahren zum screening der leichten kette eines antikörpers
JP4794301B2 (ja) 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
US20090191213A9 (en) 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
US7405275B2 (en) * 2003-09-24 2008-07-29 Millennium Pharmaceuticals, Inc. Antibodies which bind human CXCR3
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
AU2005313971B2 (en) 2004-12-08 2011-10-13 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
PT1699826E (pt) 2005-01-05 2009-06-17 F Star Biotech Forsch & Entw Domínios de imunoglobulina sintética com propriedades de ligação construídos em regiões da molécula diferentes das regiões determinantes de complementaridade
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
TWI544076B (zh) 2005-03-31 2016-08-01 Chugai Pharmaceutical Co Ltd A method of manufacturing a polypeptide that controls assembly
WO2007038392A2 (en) 2005-09-23 2007-04-05 Walter Reed Army Institute Of Research (Wrair) Antibodies with simultaneous subsite specificities to protein and lipid epitopes
DK1989231T3 (en) 2006-03-21 2015-08-24 Genentech Inc COMBINATION THERAPY INVOLVING ALFA5BETA1 antagonists
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
DK2158315T3 (en) * 2007-06-25 2016-06-06 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies and modified antibodies with improved functional properties
EP2069401A4 (en) 2007-07-31 2011-02-23 Medimmune Llc MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
WO2009032782A2 (en) * 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
KR20100065162A (ko) 2007-09-26 2010-06-15 제넨테크, 인크. 신규한 항체
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US8673310B2 (en) 2008-06-25 2014-03-18 ESBA Tech, an Alcon Biomedical Research Unit LLC Stable and soluble antibodies inhibiting TNFα
EP2310508A1 (en) 2008-07-02 2011-04-20 Emergent Product Development Seattle, LLC Tgf-b antagonist multi-target binding proteins
US8632774B2 (en) 2008-07-02 2014-01-21 Emergent Product Development Seattle, Llc Antagonists of IL-6
EA201170028A1 (ru) 2008-07-02 2011-12-30 Эмерджент Продакт Дивелопмент Сиэтл, Ллс СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ TNF-α
JP2011528035A (ja) * 2008-07-14 2011-11-10 ユーシカゴ アルゴン, エルエルシー タンパク質の安定性を体系的に制御するための方法
CA2732574A1 (en) 2008-07-28 2010-02-04 Philip Tan Multi-specific binding proteins targeting b cell disorders
KR20160120812A (ko) 2008-10-02 2016-10-18 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Cd86 길항제 다중-표적 결합 단백질
AU2010226453B2 (en) 2009-03-20 2013-11-21 Genentech, Inc. Bispecific anti-HER antibodies
CN102369215B (zh) 2009-04-02 2015-01-21 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
HRP20141032T1 (hr) 2009-09-29 2015-01-30 Roche Glycart Ag Bispecifiäśna agonistiäśka protutijela receptora smrtnosti
CN102711811A (zh) 2009-10-30 2012-10-03 拜耳医药保健有限公司 抗体模拟物支架
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
WO2011090761A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
MY166529A (en) * 2010-02-08 2018-07-10 Regeneron Pharma Common light chain mouse
WO2011109726A2 (en) * 2010-03-05 2011-09-09 Bioatla Llc Homologous multi-specific antibodies
TW201742925A (zh) * 2010-04-23 2017-12-16 建南德克公司 異多聚體蛋白質之製造
WO2012009026A2 (en) 2010-07-16 2012-01-19 Bioatla Llc Novel methods of protein evolution
CA2808482C (en) * 2010-08-16 2021-10-26 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
PH12013500974A1 (en) 2010-11-17 2013-07-08 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
EP3219728A1 (en) 2011-01-14 2017-09-20 UCB Biopharma SPRL Antibody molecules which bind il-17a and il-17f
EP2500073A1 (en) 2011-03-17 2012-09-19 ChromaCon AG Method for identification and purification of multi-specific polypeptides
CN103842383B (zh) 2011-05-16 2017-11-03 健能隆医药技术(上海)有限公司 多特异性fab融合蛋白及其使用方法
WO2013003647A2 (en) 2011-06-28 2013-01-03 Sea Lane Biotechnologies, Llc Multispecific stacked variable domain binding proteins
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
EP2543680A1 (en) 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
US8952134B2 (en) 2011-09-26 2015-02-10 Jn Biosciences Llc Hybrid constant regions
NZ631565A (en) 2012-03-14 2016-07-29 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
WO2013142255A2 (en) 2012-03-22 2013-09-26 University Of Miami Multi-specific binding agents
EP2847231B1 (en) * 2012-05-10 2019-07-10 Bioatla LLC Multi-specific monoclonal antibodies
MX2014014162A (es) 2012-05-24 2015-02-04 Hoffmann La Roche Anticuerpos multiespecificos.
CN104684928A (zh) 2012-08-02 2015-06-03 Jn生物科学有限责任公司 通过半胱氨酸突变和μ尾端多聚化的抗体或融合蛋白
KR20140036905A (ko) 2012-09-18 2014-03-26 삼성전자주식회사 이중특이 항체를 포함하는 단백질 복합체
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same

Also Published As

Publication number Publication date
MX362705B (es) 2019-02-01
AU2018201159A1 (en) 2018-03-08
JP2019088291A (ja) 2019-06-13
EP2847231A4 (en) 2016-05-25
CN108690132B (zh) 2022-10-14
JP2015517309A (ja) 2015-06-22
CN104583239B (zh) 2018-09-18
KR20190019222A (ko) 2019-02-26
HK1210620A1 (en) 2016-04-29
US20190153120A1 (en) 2019-05-23
AU2018201159B2 (en) 2020-04-30
AU2020202133B2 (en) 2023-02-16
CA2872908C (en) 2023-11-14
CA3202536A1 (en) 2013-11-14
KR102089526B1 (ko) 2020-03-17
ES2749200T3 (es) 2020-03-19
CA3051210A1 (en) 2013-11-14
EP2847231A1 (en) 2015-03-18
AU2020202133A1 (en) 2020-04-16
KR101951641B1 (ko) 2019-02-25
EP2847231B1 (en) 2019-07-10
US20180237543A1 (en) 2018-08-23
JP2018082707A (ja) 2018-05-31
KR20190073592A (ko) 2019-06-26
JP6465953B2 (ja) 2019-02-06
MX2019001355A (es) 2023-01-17
EP3553089A1 (en) 2019-10-16
JP6723392B2 (ja) 2020-07-15
MX2014013590A (es) 2015-05-11
WO2013170168A1 (en) 2013-11-14
KR20150008154A (ko) 2015-01-21
US20150252119A1 (en) 2015-09-10
AU2013259276A1 (en) 2014-11-27
US10696750B2 (en) 2020-06-30
IN2014DN09417A (OSRAM) 2015-07-17
CA2872908A1 (en) 2013-11-14
US9969813B2 (en) 2018-05-15
CN104583239A (zh) 2015-04-29
AU2013259276B2 (en) 2018-03-22
JP6267689B2 (ja) 2018-01-24
KR102023401B1 (ko) 2019-11-04
CN108690132A (zh) 2018-10-23

Similar Documents

Publication Publication Date Title
CY2024011I2 (el) Αντισωματα anti-fcrn
HUS2300021I1 (hu) Anti-IL-36R antitestek
DK2847231T3 (da) Multispecifikke monoklonale antistoffer
DK2934584T3 (da) Anti-gdf15-antistoffer
HRP20181646T1 (hr) Konjugati pirolobenzodiazepin - anti-psma protutijela
DK3653645T3 (da) Monoklonal interleukin-31-antistof
EP2714735A4 (en) SPECIFIC ANTIBODIES OF TGF BETA
CO6811812A2 (es) Anticuerpo anti-b7-h3
CR20140127A (es) Anticuerpo anti-abtcr
BR112014024769A2 (pt) anticorpo humanizado tau
EP3427721C0 (en) HIGH CONCENTRATION MONOCLONAL ANTIBODY FORMULATIONS
DK3736291T5 (da) Anti-FCRH5-antistoffer
EP2813568C0 (en) MODIFIED FC REGION OF AN ANTIBODY
EP2922874A4 (en) BISPECIFIC ANTIBODIES
BR112014024373A2 (pt) anticorpos regulados por protease
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
BR112014025037A2 (pt) anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
ME03751B (me) Antitela usmerena na beta-amiloid
HRP20181874T1 (hr) Anti-cxcr3 protutijela
DK3068800T3 (da) FcRn-specifikke antistoffer
DK3521315T3 (da) Anti-transglutaminase-2-antistoffer
DK2828292T3 (da) Jcv-neutraliserende antistoffer
DK3431504T3 (da) Antiphospholipase d4-antistof
DK2931748T3 (da) Bmp-6-antistoffer
DK2935330T3 (da) Anti-notch3-antistoffer